Scarica l'app Stockscreener
0.833
1.99%
-0.0169
Dopo l'orario di chiusura:
.84
0.007
+0.84%
Precedente Chiudi:
$0.8499
Aprire:
$0.88
Volume 24 ore:
45,140
Relative Volume:
0.02
Capitalizzazione di mercato:
$4.56M
Reddito:
-
Utile/perdita netta:
$-8.72M
Rapporto P/E:
-0.1518
EPS:
-5.4871
Flusso di cassa netto:
$-5.47M
1 W Prestazione:
+1.23%
1M Prestazione:
-28.19%
6M Prestazione:
-61.79%
1 anno Prestazione:
-71.67%
Intervallo 1D:
$0.8301
$0.88
Intervallo di 1 settimana:
$0.80
$0.88
Portata 52W:
$0.7311
$3.50
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
Nome
Galmed Pharmaceuticals Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Confronta GLMD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GLMD
Galmed Pharmaceuticals Ltd
|
0.833 | 4.66M | 0 | -8.72M | -5.47M | -5.4871 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-05-22 | Downgrade | B. Riley FBR | Buy → Neutral |
| 2020-02-04 | Iniziato | Craig Hallum | Buy |
| 2020-01-30 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-12-02 | Iniziato | Canaccord Genuity | Buy |
| 2018-12-12 | Iniziato | B. Riley FBR | Buy |
| 2018-08-02 | Reiterato | Maxim Group | Buy |
| 2018-07-13 | Iniziato | Stifel | Buy |
| 2018-07-12 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-06-12 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-15 | Aggiornamento | Maxim Group | Hold → Buy |
| 2018-02-14 | Downgrade | Maxim Group | Buy → Hold |
| 2018-02-12 | Reiterato | H.C. Wainwright | Buy |
| 2017-11-15 | Iniziato | ROTH Capital | Buy |
| 2017-08-08 | Reiterato | H.C. Wainwright | Buy |
| 2017-07-31 | Reiterato | Maxim Group | Buy |
| 2016-08-01 | Reiterato | Maxim Group | Buy |
| 2016-07-06 | Ripresa | ROTH Capital | Buy |
| 2016-03-28 | Ripresa | H.C. Wainwright | Buy |
| 2015-06-23 | Iniziato | H.C. Wainwright | Buy |
| 2015-05-06 | Iniziato | Sun Trust Rbsn Humphrey | Buy |
Mostra tutto
Galmed Pharmaceuticals Ltd Borsa (GLMD) Ultime notizie
How Galmed Pharmaceuticals Ltd. stock reacts to job market data2025 Performance Recap & Low Drawdown Momentum Ideas - ulpravda.ru
Can Galmed Pharmaceuticals Ltd. stock surprise with earnings upsideJuly 2025 Big Picture & Advanced Swing Trade Entry Alerts - ulpravda.ru
How Galmed Pharmaceuticals Ltd. (GPH) stock expands through international marketsJuly 2025 Review & Free Technical Confirmation Trade Alerts - ulpravda.ru
Is Galmed Pharmaceuticals Ltd. (GPH) stock worth buying before Fed actionJuly 2025 Drop Watch & Smart Investment Allocation Insights - ulpravda.ru
What technical charts say about Galmed Pharmaceuticals Ltd. stock2025 Market WrapUp & Reliable Volume Spike Alerts - ulpravda.ru
What drives Galmed Pharmaceuticals Ltd GPH stock priceTrade Execution Strategies & Small Capital Investment Tips - earlytimes.in
EBIT per share of Galmed Pharmaceuticals Ltd. – BER:GPH - TradingView — Track All Markets
Will Galmed Pharmaceuticals Ltd. stock outperform tech sector in 2025Market Sentiment Surveys & Free Rapid Wealth Multiplication - bollywoodhelpline.com
Is Galmed Pharmaceuticals Ltd. stock a defensive play in 2025Evening Star Patterns & High Profit Market Ideas - bollywoodhelpline.com
Downgrade Watch: Why Galmed Pharmaceuticals Ltd stock is seen as undervalued2025 Short Interest & Weekly Breakout Stock Alerts - moha.gov.vn
Financial Survey: Galmed Pharmaceuticals (NASDAQ:GLMD) vs. Qualigen Therapeutics (NASDAQ:QLGN) - Defense World
Will Galmed Pharmaceuticals Ltd. stock benefit from upcoming earnings reportsJuly 2025 Review & Low Drawdown Investment Strategies - Улправда
Aug Selloffs: How interest rate cuts could boost Galmed Pharmaceuticals Ltd. stock2025 Key Lessons & Long-Term Growth Portfolio Plans - Улправда
How interest rate cuts could boost Galmed Pharmaceuticals Ltd. stock2025 Price Action Summary & Daily Stock Trend Watchlist - Улправда
Galmed Pharmaceuticals (NASDAQ:GLMD) Share Price Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
How big funds are accumulating Galmed Pharmaceuticals Ltd. (GPH) stockMarket Capitalization Trends & Outperform the Market with Aggressive Picks - Bollywood Helpline
Is Galmed Pharmaceuticals Ltd. (GPH) stock a safe buy pre earningsMarket Trend Review & Weekly Top Gainers Trade List - DonanımHaber
Galmed to present data on Aramchol’s potential in liver cancer By Investing.com - Investing.com Canada
Galmed to present data on Aramchol’s potential in liver cancer - Investing.com
Galmed Pharmaceuticals’ Aramchol Abstract Accepted for HEP-DART 2025 Presentation - TipRanks
Galmed Pharmaceuticals’ Aramchol abstract accepted for HEP-DART 2025 presentation - MSN
Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting - PR Newswire
Galmed receives patent for combination therapy in South Korea By Investing.com - Investing.com Nigeria
Can Galmed Pharmaceuticals Ltd. (GPH) stock surprise with quarterly resultsBuy Signal & Weekly Breakout Watchlists - Newser
Galmed Announces Grant of New Use Patents for the Combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra for Mash - marketscreener.com
Galmed stock rises after patent grant for MASH combo therapy By Investing.com - Investing.com Nigeria
Galmed stock rises after patent grant for MASH combo therapy - Investing.com
Galmed receives patent for combination therapy in South Korea - Investing.com
Galmed Pharmaceuticals Secures New Patent for Aramchol Combination Therapy - TipRanks
Galmed announces grant of new use patents for the combination of Aramchol and Madrigal Pharmaceuticals - marketscreener.com
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH - PR Newswire
Can Galmed Pharmaceuticals Ltd. (GPH) stock sustain free cash flowQuarterly Trade Review & Accurate Trade Setup Notifications - Newser
Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Passes Below 200-Day Moving Average – Should You Sell? - Defense World
Is Galmed Pharmaceuticals Ltd. (GPH) stock supported by strong fundamentals2025 EndofYear Setup & Risk Managed Investment Signals - Newser
Is Galmed Pharmaceuticals Ltd. (GPH) stock good for long term investing - Newser
Can Galmed Pharmaceuticals Ltd. (GPH) stock attract ESG investmentsTrade Volume Summary & High Accuracy Investment Signals - Newser
Galmed Pharmaceuticals Shares Edge Higher Following CEO’s Positive Update - MSN
Galmed Pharmaceuticals Expands Aramchol’s Clinical Applications and Strengthens Financial Position - MSN
Is Galmed Pharmaceuticals Ltd. (GPH) stock positioned for digital growth era2025 Trading Volume Trends & Real-Time Buy Signal Notifications - Newser
Galmed Pharmaceuticals Ltd Azioni (GLMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):